drugset
drugset / Trial / NCT03563794

Efficacy and Safety of Vildagliptin Added to Continuous Subcutaneous Insulin Infusion in Uncontrolled Type 2 Diabetes

NCT03563794 ↗

Phase 4 Unknown 400 enrolled The First Affiliated Hospital of Xiamen University
RandomizedParallel-groupOpen-labelTreatment

Summary

The randomized, controlled clinical trial investigate the efficacy and safety of vildagliptin added to continuous subcutaneous insulin infusion in uncontrolled type 2 diabetes

Timeline

Start
2018-06-10
Primary completion
2019-06-10
Completion
2019-12-10

Drugs

EvaluationDrugModalityDoseRoute
Subject Vildagliptin Other / unclassified 50 mg Oral
Comparator Insulin Lispro Protein / enzyme biologic — Subcutaneous

Indications

type 2 diabetes mellitus